Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IncobotulinumtoxinA is a purified form of botulinum toxin type A, produced by the bacterium *Clostridium botulinum*. It acts as a neuromuscular blocker and is used to treat several conditions involving muscle overactivity or excessive glandular secretion. Its mechanism involves inhibiting the release of acetylcholine at presynaptic nerve terminals, thereby reducing muscle contractions or glandular activity. IncobotulinumtoxinA is indicated for chronic sialorrhea (excessive drooling), upper limb spasticity in adults and children (excluding those with cerebral palsy), cervical dystonia (spasmodic torticollis), blepharospasm (eyelid spasms), and temporary improvement of moderate to severe upper facial lines such as glabellar lines, forehead lines, and crow’s feet in adults[1][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on incobotulinumtoxinA.